X4 Pharmaceuticals, Inc.

NasdaqCM:XFOR Lagerbericht

Marktkapitalisierung: US$87.5m

X4 Pharmaceuticals Management

Management Kriterienprüfungen 3/4

X4 Pharmaceuticals' CEO is Paula Ragan, appointed in Jul 2014, has a tenure of 10.33 years. total yearly compensation is $2.04M, comprised of 30.3% salary and 69.7% bonuses, including company stock and options. directly owns 0.61% of the company’s shares, worth $532.39K. The average tenure of the management team and the board of directors is 3.6 years and 5.7 years respectively.

Wichtige Informationen

Paula Ragan

Geschäftsführender

US$2.0m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts30.3%
Amtszeit als Geschäftsführer10.3yrs
Eigentum des Geschäftsführers0.6%
Durchschnittliche Amtszeit des Managements3.6yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder5.7yrs

Jüngste Management Updates

Recent updates

X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data

Jul 02

Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?

Mar 26
Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?

Is X4 Pharmaceuticals (NASDAQ:XFOR) A Risky Investment?

Apr 19
Is X4 Pharmaceuticals (NASDAQ:XFOR) A Risky Investment?

Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Too Much Debt?

Oct 07
Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Too Much Debt?

X4 Pharmaceuticals: Upcoming Catalysts

Sep 19

X4 Pharma to focus resources on lead drug candidate, cut workforce by about 20%

Jul 20

X4 Pharmaceuticals to raise $55M in stock and warrants offering, debt facility amended

Jul 01

X4 Pharma: Late Stage Nanocap Targeting Rare Diseases

Aug 03

Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Debt Sensibly?

Jun 22
Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Debt Sensibly?

X4 Pharmaceuticals EPS misses by $0.44

May 06

How Many X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Shares Do Institutions Own?

Mar 16
How Many X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Shares Do Institutions Own?

X4 Pharmaceuticals EPS misses by $0.12

Nov 05

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Paula Ragan im Vergleich zu den Einnahmen von X4 Pharmaceuticals verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Jun 30 2024n/an/a

US$18m

Mar 31 2024n/an/a

-US$129m

Dec 31 2023US$2mUS$620k

-US$101m

Sep 30 2023n/an/a

-US$111m

Jun 30 2023n/an/a

-US$131m

Mar 31 2023n/an/a

-US$96m

Dec 31 2022US$4mUS$583k

-US$96m

Sep 30 2022n/an/a

-US$103m

Jun 30 2022n/an/a

-US$102m

Mar 31 2022n/an/a

-US$100m

Dec 31 2021US$2mUS$562k

-US$103m

Sep 30 2021n/an/a

-US$85m

Jun 30 2021n/an/a

-US$82m

Mar 31 2021n/an/a

-US$78m

Dec 31 2020US$3mUS$543k

-US$62m

Sep 30 2020n/an/a

-US$55m

Jun 30 2020n/an/a

-US$55m

Mar 31 2020n/an/a

-US$53m

Dec 31 2019US$2mUS$492k

-US$53m

Sep 30 2019n/an/a

-US$55m

Jun 30 2019n/an/a

-US$46m

Mar 31 2019n/an/a

-US$40m

Dec 31 2018US$921kUS$380k

-US$36m

Vergütung im Vergleich zum Markt: Paula's total compensation ($USD2.04M) is above average for companies of similar size in the US market ($USD655.65K).

Entschädigung vs. Einkommen: Paula's compensation has been consistent with company performance over the past year.

Geschäftsführer

Paula Ragan (54 yo)

10.3yrs

Amtszeit

US$2,044,761

Vergütung

Dr. Paula Ragan, Ph D., is Member of Advisory Board of Tippingpoint Biosciences, Inc. Dr. Ragan serves as an Independent Director of CAMP4 Therapeutics Corporation since May 2019. She is a Founder of X4 Ph...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Paula Ragan
CEO, President & Director10.3yrsUS$2.04m0.61%
$ 532.4k
Adam Mostafa
CFO, Treasurer & Corporate Secretary6.2yrsUS$1.15mkeine Daten
Christophe Arbet-Engels
Chief Medical Officer1.3yrsUS$1.64mkeine Daten
Richard Peters
Founderno datakeine Datenkeine Daten
Renato Skerlj
Founderno datakeine Datenkeine Daten
Keith Flaherty
Founder & Member of Corporate Advisory Boardno datakeine Datenkeine Daten
Mary DiBiase
Chief Operating Officer3.2yrsUS$1.84m0.27%
$ 234.6k
Arthur Taveras
Chief Scientific Officer4yrskeine Daten0.23%
$ 201.4k
Robert Arbeit
Senior Vice President of Clinical Development and Translational Researchno datakeine Datenkeine Daten
Mark Baldry
Chief Commercial Officer2yrskeine Daten0.029%
$ 25.2k

3.6yrs

Durchschnittliche Betriebszugehörigkeit

60yo

Durchschnittliches Alter

Erfahrenes Management: XFOR's management team is considered experienced (3.6 years average tenure).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Paula Ragan
CEO, President & Director10.3yrsUS$2.04m0.61%
$ 532.4k
Keith Flaherty
Founder & Member of Corporate Advisory Board8.6yrskeine Datenkeine Daten
Michael Wyzga
Independent Chairman of the Board6.3yrsUS$199.34k0.045%
$ 39.8k
Gary Bridger
Director5.7yrsUS$147.05k0.031%
$ 26.8k
David W. McGirr
Independent Director7.2yrsUS$166.05k0.031%
$ 26.8k
Alison Lawton
Independent Director4.1yrsUS$154.55k0.031%
$ 26.8k
William Aliski
Independent Director5.2yrsUS$165.05k0.031%
$ 26.8k
Michael Vasconcelles
Member of Corporate Advisory Board8.6yrskeine Datenkeine Daten
Robert Woods
Independent Director1.1yrsUS$91.83kkeine Daten
Murray Stewart
Director5.7yrsUS$90.08k0.087%
$ 76.0k
Francoise de Craecker
Independent Director3.1yrsUS$152.05k0.031%
$ 26.8k

5.7yrs

Durchschnittliche Betriebszugehörigkeit

62yo

Durchschnittliches Alter

Erfahrener Vorstand: XFOR's board of directors are considered experienced (5.7 years average tenure).